Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05865301 · ClinicalTrials.gov registry record
Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy
A clinical trial of Lymphoid Leukemia, sponsored by Stanford University.
- Recruiting
- Registry status
- 500
- Enrollment target
- 20
- Study locations
NCT05865301: Recruiting study of Lymphoid Leukemia, sponsored by Stanford University.
NCT05865301 is a study of Lymphoid Leukemia that is actively recruiting participants, run by Stanford University. The registered enrollment target is 500 participants, above the 23-participant average among 3 other Lymphoid Leukemia trials with a reported enrollment target (2074% higher). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05865301, a study of Lymphoid Leukemia, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 20
- Study locations
Study Summary
To use a consistent and standardized platform to retrospectively and prospectively study children and young adults with B cell malignancies receiving Immunotherapy, blinatumomab and/or inotuzumab ozogamicin.
Conditions Studied
Interventions
- OTHER Questionnaire for patients receiving therapy
Study Locations (20)
California
- City of Hope Comprehensive Cancer Center - Duarte
- Stanford University - Palo Alto
- UCSF (Benioff Children's) - San Francisco
Florida
- University of Florida Health Science Center - Gainesville - Gainesville
- Johns Hopkins All Children's Hospital - St. Petersburg
Texas
- UT Southwestern/Simmons Cancer Center-Dallas - Dallas
- Cook Children's Medical Center - Fort Worth
Arizona
- Banner University Medical Center - Tucson - Tucson
Delaware
- Nemours Children's Hospital - New Castle
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
Maryland
- Johns Hopkins University/Sidney Kimmel Cancer Center - Baltimore
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2023-06-29 |
| Est. Completion | 2038-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05865301
The ClinicalTrials.gov registry entry for NCT05865301 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 23-participant average among 3 other Lymphoid Leukemia trials with a reported enrollment target (2074% higher). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lymphoid Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Questionnaire for patients receiving therapy is the first listed.
NCT05865301 reports 20 study locations spanning 16 distinct geographic areas - top geographies include California, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT05865301 about?
NCT05865301 is a clinical study titled "Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy". To use a consistent and standardized platform to retrospectively and prospectively study children and young adults with B cell malignancies receiving Immunotherapy, blinatumomab and/or inotuzumab ozogamicin.
What is the current status of trial NCT05865301?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2023-06-29. Estimated completion is 2038-12-31.
What conditions does trial NCT05865301 study?
This clinical trial studies the following conditions: Lymphoid Leukemia.
What interventions are being tested in trial NCT05865301?
The interventions under investigation include: Questionnaire for patients receiving therapy (OTHER).
Who is sponsoring clinical trial NCT05865301?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05865301 being conducted?
This trial has 20 study locations across Arizona, California, Delaware, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Myeloablative Conditioning Orca-T & Allogeneic Donor-Derived CD19/CD22-CAR TCells in B-Cell ALL
ACTIVE NOT RECRUITING · Phase 1
-
Integrated Actionable Aging Assessment for Cancer Patients Pilot
ACTIVE NOT RECRUITING · NA
-
Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia
COMPLETED · Phase 2
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.